ALX ONCOLOGY HOLDINGS INC. - COMMON STOCK

ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

17 5 2021 15:05:01 提供 Nasdaq GlobeNewswire

ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma

10 5 2021 06:00:00 提供 Nasdaq GlobeNewswire

ALX Oncology to Present ALX148 Clinical Data at the ESMO 23rd World Congress on Gastrointestinal Cancer

21 4 2021 15:05:00 提供 Nasdaq GlobeNewswire

ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148

05 4 2021 06:00:00 提供 Nasdaq GlobeNewswire

ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

18 3 2021 15:05:00 提供 Nasdaq GlobeNewswire

ALX Oncology Announces Appointment of Sophia Randolph, M.D., Ph.D., to Board of Directors

15 3 2021 06:00:02 提供 Nasdaq GlobeNewswire

ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics

04 3 2021 15:05:00 提供 Nasdaq GlobeNewswire

ALX Oncology to Participate at H.C. Wainwright Global Life Sciences Conference

02 3 2021 06:00:02 提供 Nasdaq GlobeNewswire

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2021

11 1 2021 06:00:01 提供 Nasdaq GlobeNewswire

ALX Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference

05 1 2021 06:00:00 提供 Nasdaq GlobeNewswire